Sidewinder Therapeutics
Develops next-generation bispecific ADCs for cancer treatment
$137MSeries B
Role not disclosedActivity from announced rounds
Develops next-generation bispecific ADCs for cancer treatment
Develops novel multifunctional antibodies for oncology and immunology & inflammation indications